These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The role of prophylactic implantable cardioverter defibrillators in heart failure: recent trials usher in a new era of device therapy. Brennan TD; Haas GJ Curr Heart Fail Rep; 2005 Mar; 2(1):40-5. PubMed ID: 16036050 [TBL] [Abstract][Full Text] [Related]
27. [ICD-implantation--for which patients is its value for primary prevention secure?]. Fiek M; Reithmann C; Steinbeck G Dtsch Med Wochenschr; 2006 Sep; 131(39):2165-8. PubMed ID: 16991035 [No Abstract] [Full Text] [Related]
28. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Zareba W; Piotrowicz K; McNitt S; Moss AJ; Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580 [TBL] [Abstract][Full Text] [Related]
29. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. Al-Khatib SM; Fonarow GC; Joglar JA; Inoue LYT; Mark DB; Lee KL; Kadish A; Bardy G; Sanders GD JAMA Cardiol; 2017 Jun; 2(6):685-688. PubMed ID: 28355432 [TBL] [Abstract][Full Text] [Related]
30. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Fonarow GC; Feliciano Z; Boyle NG; Knight L; Woo MA; Moriguchi JD; Laks H; Wiener I Am J Cardiol; 2000 Apr; 85(8):981-5. PubMed ID: 10760339 [TBL] [Abstract][Full Text] [Related]
31. Deactivation of implantable cardioverter-defibrillators: results of patient surveys. Herman D; Stros P; Curila K; Kebza V; Osmancik P Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573 [TBL] [Abstract][Full Text] [Related]
33. [Factors predisposing to the reprogramming of implantable cardioverter-defibrillators and the causes of changes in pharmacotherapy in patients with dilated cardiomyopathy for primary prevention of sudden cardiac death]. Pudło J; Liszniański P; Senderek T; Lelakowska-Pieła M; Lelakowski J; Nowak J Pol Merkur Lekarski; 2015 Aug; 39(230):86-90. PubMed ID: 26319381 [TBL] [Abstract][Full Text] [Related]
34. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. Klein MH; Gold MR Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188 [TBL] [Abstract][Full Text] [Related]
35. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294 [TBL] [Abstract][Full Text] [Related]
36. Indications for implantable cardioverter defibrillator (ICD) therapy. Hauer RN; Aliot E; Block M; Capucci A; Lüderitz B; Santini M; Vardas PE; Europace; 2001 Jul; 3(3):169-76. PubMed ID: 11467456 [No Abstract] [Full Text] [Related]
37. The timing of implantable cardioverter-defibrillator implantation in patients with heart failure. Al-Majed NS; Ezekowitz JA Curr Cardiol Rep; 2012 Jun; 14(3):299-307. PubMed ID: 22426975 [TBL] [Abstract][Full Text] [Related]